Release Date: 25/08/20 08:04 Summary: FY20 Results Investor Presentation Price Sensitive: Yes Download Document 2.33MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%